➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Medtronic
Boehringer Ingelheim
Dow
AstraZeneca

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Trilaciclib dihydrochloride - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic drug sources for trilaciclib dihydrochloride and what is the scope of freedom to operate?

Trilaciclib dihydrochloride is the generic ingredient in one branded drug marketed by G1 Therap and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Trilaciclib dihydrochloride has one hundred and six patent family members in twenty-five countries.

Summary for trilaciclib dihydrochloride
International Patents:106
US Patents:10
Tradenames:1
Applicants:1
NDAs:1
Clinical Trials: 10
DailyMed Link:trilaciclib dihydrochloride at DailyMed
Recent Clinical Trials for trilaciclib dihydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 4
G1 Therapeutics, Inc.Phase 4
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 3

See all trilaciclib dihydrochloride clinical trials

US Patents and Regulatory Information for trilaciclib dihydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for trilaciclib dihydrochloride

Country Patent Number Estimated Expiration
Japan 2016514689 ⤷  Free Forever Trial
Cyprus 1118004 ⤷  Free Forever Trial
South Korea 20190135556 ⤷  Free Forever Trial
European Patent Office 3118203 ⤷  Free Forever Trial
European Patent Office 2968291 ⤷  Free Forever Trial
South Korea 20140003427 ⤷  Free Forever Trial
Japan 2020128408 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Medtronic
Boehringer Ingelheim
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.